Senior executive brings over 30 years of experience in global biopharmaceutical operations and program management
MIAMI, Sept. 15, 2022 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative drugs for unmet medical needs, today announced the appointment of Jerome Bailey to position as the new Vice President of Corporate Business Operations. He joins the company from Checkmate Pharmaceuticals (acquired by Regeneron), where he served as Senior Director of Program Management. Mr. Bailey brings to the company more than 30 years of operational leadership and program management experience in the biopharmaceutical industry, overseeing clinical trials from phase 1 to phase 4 in several therapeutic areas.
“As we continue to grow and evolve, building our portfolio of regenerative drugs, we are thrilled to have someone of Jerome’s caliber and experience join our team,” said Chris Min, MD, Ph.D. ., interim CEO and Medical Director. Officer of Longeveron. “Jerome’s extensive experience in portfolio management and clinical operations across multiple therapeutic areas makes him an invaluable addition to our team as we advance our flagship medicinal signaling cell therapy product, Lomecel-B™, through through clinical trials in three indications.
“I am delighted to join the Longeveron team,” said Mr. Bailey. “The company is poised for a period of explosive growth with phase 2 trials in Alzheimer’s disease and hypoplastic left heart syndrome (HLHS) underway, and the planned launch of the phase 2 trial in frailty related to aging in Japan. I look forward to working with the exceptional team at Longeveron to continue advancing the company’s strong pipeline through the next clinical stages. »
Prior to joining Longeveron, Mr. Bailey was Senior Director of Program Management at Checkmate Pharmaceuticals, where he led cross-functional project teams driving multiple oncology programs from candidate screening through clinical development. Prior to Checkmate Pharmaceuticals, he held positions of increasing responsibility at Parexel, where he led several global development programs in several therapeutic areas, including oncology, hematology, pulmonary and rare pediatric diseases. He also facilitated the product submission strategy in several major global schizophrenia and hypertension markets. Prior to Parexel, Mr. Bailey held leadership positions at Applied Clinical Intelligence, Theorem Clinical Research, BDH Clinical Research, Covance and Eli Lilly. Mr. Bailey began his career as a clinical researcher at Ayerst Laboratories, then at Hoffman La Roche. Mr. Bailey holds a BS in Biological Sciences from Rutgers University.
About Longeveron Inc.
Longeveron is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapeutic product isolated from the bone marrow of healthy young adult donors. Lomecel-B™ has a multimodal mechanism of action that is pro-vascular, pro-regenerative and anti-inflammatory, promoting tissue repair and healing with broad potential applications in a wide range of disease areas. Longeveron is advancing Lomecel-B™ through clinical trials in three indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and frailty associated with aging. Additional information about the Company is available at www.longeveron.com.
Caution Regarding Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions and estimates regarding future performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking words such as “believes”, “expects”, “may”, “hopes”, “will”, “should”, “plans”, “has intent to”, “provided”, “target”, “see”, “potential”, “estimates”, “preliminary” or “anticipate” or the negative thereof or comparable terminology, or through a discussion of the strategy or objectives or other future events or circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements in this release include, but are not limited to, statements about the ability of clinical trials of Longeveron to demonstrate the safety and efficacy of the Company’s product candidates, and other positive results; the timing and orientation of the Company’s ongoing and future preclinical studies and clinical trials and the communication of data from these studies and trials; the size of the market opportunity for the Company’s product candidates, including its estimates of the number of patients suffering from the targeted diseases; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company’s product candidates; the Company’s ability to obtain and maintain regulatory approval for its product candidates; the Company’s plans for further development of its product candidates, including any additional disease states or indications it may pursue; existing regulations and regulatory developments in the United States, Japan and other jurisdictions; the Company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms when available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company’s ability to attract and retain such personnel; the Company’s estimates of expenses, future revenues, capital needs and additional financing needs; the Company’s need to raise additional capital, the difficulties it may encounter in accessing capital and the dilutive impact it may have on its investors; the Company’s financial performance and the period over which it estimates that its cash and cash equivalents will be sufficient to fund its future operating and capital expenditures. Further information regarding factors that could affect the Company’s results and forward-looking statements is disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10. -K for the fiscal year ended December 31, 2021, filed with the SEC on March 11, 2022, and the company’s quarterly reports on Form 10-Q for the periods ended March 31, 2022 and June 30, 2022. The statements forward-looking statements contained in this press release are made as of the date of this press release, and the Company disclaims any intention or obligation, other than required by law, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Stern IR, Inc.